SH2B2

Across TCGA pan-cancer cohorts, SH2B2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SH2B2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SH2B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH2B2 expression acts as an unfavorable survival marker.

KIRC, BLCA, and KIRP are the cancer types where SH2B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.037	0.881	<.001	42	view →
BLCA	DFS	Median	All	0.139	0.626	.010	12	view →
KIRP	DFS	Median	All	0.178	0.867	<.001	6	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	II,III,IV	0.192	0.752	.038	3	view →
COAD	OS	Median	All	0.207	0.675	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SH2B2–KIRC (OS)

Open the KIRC breakdown →